Disease-Modifying Antirheumatic Drug (DMARD) Market to Surpass US$ 27,167.8 Mn by 2030

Global Disease-Modifying Antirheumatic Drug (DMARD) Market, by Drug Type (Synthetic (sDMARD), (Conventional synthetic (csDMARDs), (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine and Gold Salts), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD), (Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs), (Primary, Secondary and Tertiary) and Others), by Route of Administration (Oral, Parenteral and Others), by Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Systemic Lupus Erythematosus and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) is estimated to be valued at US$  20,671.1 Mn in 2022 and is expected to exhibit a CAGR of 3.5% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Key trends in the market include increasing launches of research projects which is expected to drive the growth over the forecast period. For instance, in April 2022, AbbVie Inc is a specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Global Disease-Modifying Antirheumatic Drug (DMARD) Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs (Contract research organizations), and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic. In April 2020 study for the Impact of COVID-19 on clinical trial sites conducted by Medidata, a life sciences software provider that supports clinical trials with a primary focus on evidence generation, suggests that investigative sites demonstrated flexibility and ingenuity in adopting new approaches in order to cope with challenges presented by the pandemic, with over half of investigative sites transitioning to virtual approaches to interact with patients. Follow-up studies performed in August 2020 have identified persistent impact of COVID-19 pandemic, with over 60% reporting an average or greater level of impact on ongoing trials and initiation of new trials. Respondents specifically highlighted challenges in patient enrollment and recruitment. Recently, the U.S. FDA guidance (March 2020 and updated July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or put new processes in place of current protocols. Therefore, there are now more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-traditional approaches that do not involve in-person visits.

Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Disease-Modifying Antirheumatic Drug (DMARD) Market”- Forecast to 2030, Global Disease-Modifying Antirheumatic Drug (DMARD) Market, by Drug Type (Synthetic (sDMARD), (Conventional synthetic (csDMARDs), (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine and Gold Salts), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD), (Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs), (Primary, Secondary and Tertiary) and Others), by Route of Administration (Oral, Parenteral and Others), by Indication (Rheumatoid Arthritis, Ankylosing Spondylitis. Psoriatic Arthritis, Systemic Lupus Erythematosus and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa)

To know the latest trends and insights prevalent in the Disease-Modifying Antirheumatic Drug (DMARD) Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/disease-modifying-antirheumatic-drug-market-5185

Moreover, increasing prevalence of psoriatic arthritis is expected to drive the market growth over the forecast period. For instance, according to data published in National Center for Biotechnology Information, in January 2019,  in children and adolescents (<18 years of age), the pooled prevalence was 3.3% in 2018. The psoriatic arthritis (PsA) prevalence was 22.7% in the European patients with psoriasis, 21.5% in the South American patients with psoriasis, 19.5% in the North American patients with psoriasis, 15.5% in the African patients with psoriasis, and 14.0% in the Asian patients with psoriasis inn 2018.

Key Takeaways of the Global Disease-Modifying Antirheumatic Drug (DMARD) Market:   

• The global disease-modifying antirheumatic drug (DMARD) market is expected to exhibit a CAGR of 3.5% during the forecast period due to increasing product approvals for rheumatoid arthritis which is expected to boost the growth of the market. For instance, in June 2018, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) had approved the 2-mg dose of OLUMIANT (baricitinib), a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies.
• Based on distribution channel, hospital pharmacy segment is estimated to hold a dominant position in global disease-modifying antirheumatic drug (DMARD) market over the forecast period owing to increasing hospitalization for systemic lupus erythematosus. For instance according to data published by PubMed in January 2021, the mean crude hospitalization rate for systemic lupus erythematosus (SLE) calculated was 29.8% in 2020 in U.A.E. The primary reason for admission was pregnancy (29%), SLE activity (24%), and infection (20%). When combining primary and secondary reasons, the proportion of admissions due to SLE activity increased to 32 in 2020 in U.A.E.
• Among regions, Asia Pacific is estimated to exhibit largest CAGR in the global disease-modifying antirheumatic drug (DMARD) market over the forecast period owing to key players in the market focusing on inorganic growth strategies such as licensing agreements for disease-modifying antirheumatic drug. For instance, in June 2019, Sun Pharmaceutical Industries Ltd. is an Indian multinational pharmaceutical company, announced that one of its wholly owned subsidiaries had entered into a licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS), is a well-established, innovation-driven specialty pharma company with focus on sales and marketing in China, for the development and commercialization of Tildrakizumab, an innovative biologic product, for psoriasis and psoriatic arthritis in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan)
• Major players operating in the global disease-modifying antirheumatic drug (DMARD) market include Sanofi., Pfizer,  Hoffman-La Roche AG,  Johnson & Johnson,  AbbVie Inc., Eli Lilly & Company,  Amgen Inc.,  Swedish Orphan Biovitrum AB,  Bristol-Myers Squibb Company,  UCB S.A.,  Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.